SPRINGWORKS THERAPEUTICS INC. - COMMON STOCK

SpringWorks Therapeutics to Participate in the Jefferies London Healthcare Conference

12 Nov 2024 09:25:59 By Nasdaq GlobeNewswire

SpringWorks Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

12 Nov 2024 06:30:21 By Nasdaq GlobeNewswire

SpringWorks Therapeutics Announces Mirdametinib Data to be Presented at the 2024 Society for Neuro-Oncology (SNO) Annual Meeting

11 Nov 2024 07:00:56 By Nasdaq GlobeNewswire

SpringWorks Therapeutics Announces Publication of the Pivotal Phase 2b ReNeu Trial Evaluating Mirdametinib in Adults and Children with NF1-PN in the Journal of Clinical Oncology

11 Nov 2024 06:30:11 By Nasdaq GlobeNewswire

SpringWorks Therapeutics Announces Long-Term Efficacy and Safety Data from Phase 3 DeFi Trial of OGSIVEO® (nirogacestat) in Adults with Desmoid Tumors to be Presented at the Connective Tissue Oncology Society (CTOS) 2024 Annual Meeting

07 Nov 2024 06:30:00 By Nasdaq GlobeNewswire

SpringWorks Therapeutics to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference

05 Nov 2024 07:00:32 By Nasdaq GlobeNewswire

SpringWorks Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024

22 Oct 2024 07:00:14 By Nasdaq GlobeNewswire

FDA Grants Priority Review to SpringWorks Therapeutics’ New Drug Application for Mirdametinib for the Treatment of Adults and Children with NF1-PN

28 Aug 2024 06:30:35 By Nasdaq GlobeNewswire

SpringWorks Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

07 Aug 2024 06:30:35 By Nasdaq GlobeNewswire

SpringWorks Therapeutics Appoints Dr. Martin Mackay to its Board of Directors

29 Jul 2024 06:30:11 By Nasdaq GlobeNewswire

SpringWorks Therapeutics to Report Second Quarter 2024 Financial Results on Wednesday, August 7, 2024

23 Jul 2024 07:00:02 By Nasdaq GlobeNewswire

SpringWorks Therapeutics Completes Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN

01 Jul 2024 06:30:00 By Nasdaq GlobeNewswire

SpringWorks Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

05 Jun 2024 07:00:52 By Nasdaq GlobeNewswire

SpringWorks Therapeutics Announces Data to be Presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

23 May 2024 17:13:28 By Nasdaq GlobeNewswire

SpringWorks Therapeutics to Participate in the BofA Securities 2024 Health Care Conference

08 May 2024 07:00:27 By Nasdaq GlobeNewswire

SpringWorks Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates

02 May 2024 06:30:00 By Nasdaq GlobeNewswire

SpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

24 Apr 2024 13:31:32 By Nasdaq GlobeNewswire

SpringWorks Therapeutics to Report First Quarter 2024 Financial Results Thursday, May 2, 2024

18 Apr 2024 07:00:28 By Nasdaq GlobeNewswire

SpringWorks Therapeutics Initiates Rolling Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN

04 Mar 2024 06:30:11 By Nasdaq GlobeNewswire

SpringWorks Therapeutics Announces European Medicines Agency Validation for Marketing Authorization Application of Nirogacestat for the Treatment of Adults with Desmoid Tumors

29 Feb 2024 08:30:13 By Nasdaq GlobeNewswire